XIAP and non-small cell lung carcinoma: Our rationale was to investigate whether XIAP inhibition with XAC 1396-11, in NSCLC, could sensitise to chemotherapy with the potential to dose-reduce cytotoxic treatment, thus preventing chemotherapy-induced toxicity but maintaining therapeutic efficacy.